登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由中国人民解放军总医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07489989,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 85 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed CD19 and/or CD22-positive large B-cell lymphoma (LBCL) according to the WHO 2016 classification, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), and related entities, with one of the following:
入选标准第 1 条
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements ("double-hit" or "triple-hit") confirmed by fluorescence in situ hybridization (FISH);
入选标准第 5 条
Partial response (PR) after induction therapy with a standard first-line chemotherapy regimen (e.g., R-CHOP for 4-6 cycles); or
入选标准第 2 条
Less than 50% tumor reduction or disease progression after ≥4 cycles of standardized chemotherapy;
入选标准第 13 条
Relapse within 6 months after achieving CR with standard regimen;
入选标准第 14 条
History of other malignancy, unless the patient has been disease-free and has received no antitumor therapy for at least 3 years (exceptions: non-melanoma skin cancer, and carcinoma in situ of the cervix, bladder, or breast).
排除标准第 11 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
入选标准第 19 条
Hemoglobin (HGB) ≥60 g/L (transfusion permitted).
入选标准第 21 条
Absolute neutrophil count (ANC) ≥1,000/μL and platelet count ≥45,000/μL.
入选标准第 22 条
Total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN) (except for patients with Gilbert's syndrome);
入选标准第 24 条
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN;
入选标准第 25 条
Serum creatinine (Cr) ≤1.5 × ULN **or** creatinine clearance (CCr) ≥60 mL/min (estimated by Cockcroft-Gault formula);
入选标准第 26 条
Non-hematologic malignancy-related hepatic or renal impairment, including any of the following: ALT > 3 × ULN, AST > 3 × ULN, total bilirubin (TBIL) > 2 × ULN, or creatinine clearance < 30 mL/min.
排除标准第 5 条
Female patients who are pregnant or breastfeeding (preconditioning chemotherapy regimen poses potential risk to the fetus or infant).
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07489989,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Histologically or cytologically confirmed CD19 and/or CD22-positive large B-cell lymphoma (LBCL) according to the WHO 2016 classification, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), and related entities, with one of the following: Partial response (PR) after induction therapy with a standard first-line chemotherapy regimen (e.g., R-CHOP for 4-6 cycles); or Complete response (CR) after standard first-line induction therapy, but with high-risk features present at initial diagnosis. Presence of high-risk features at initial diagnosis, defined as at least one of the following: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements ("double-hit" or "triple-hit") confirmed by fluorescence in situ hybridization (FISH); High-grade B-cell lymphoma with 11q aberration (Burkitt-like lymphoma with 11q aberration); International Prognostic Index (IPI) score of 2-5; age-adjusted IPI (aa-IPI) score of 2-3; or National Comprehensive Cancer Network-IPI (NCCN-IPI) score of 4-8; CD5 positivity by immunohistochemistry; Dual expression of MYC and BCL2 by immunohistochemistry (recommended thresholds: MYC ≥ 40% and BCL2 ≥ 50%); TP53 mutation detected by gene sequencing; Molecular subtype MCD or N1 by next-generation sequencing (NGS); Relapsed/refractory B-cell lymphoma, meeting one of criteria ①-④ plus criterion ⑤: Less than 50% tumor reduction or disease progression after ≥4 cycles of standardized chemotherapy; Relapse within 6 months after achieving CR with standard regimen; ≥2 relapses after CR; Relapse after hematopoietic stem cell transplantation; Must have received adequate prior therapy, including at least an anti-CD20 monoclonal antibody and anthracycline-containing combination chemotherapy. Age 18 to 85 years, male or female. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Expected survival of >3 months from the date of signing informed consent. Hemoglobin (HGB) ≥60 g/L (transfusion permitted). Absolute neutrophil count (ANC) ≥1,000/μL and platelet count ≥45,000/μL. Adequate hepatic, renal, cardiac, and pulmonary function, meeting **all** of the following: Total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN) (except for patients with Gilbert's syndrome); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; Serum creatinine (Cr) ≤1.5 × ULN **or** creatinine clearance (CCr) ≥60 mL/min (estimated by Cockcroft-Gault formula); Left ventricular ejection fraction (LVEF) ≥50% by echocardiogram (ECHO), with no pericardial effusion and no clinically significant arrhythmias; Baseline oxygen saturation by pulse oximetry >92% on room air; No clinically significant pleural effusion.排除标准:Exclusion Criteria:
Patients eligible for CAR-T cell immunotherapy must **NOT** meet any of the following exclusion criteria: Prior treatment with any form of chimeric antigen receptor (CAR) T-cell therapy or other genetically modified T-cell therapy. History of severe immediate-type hypersensitivity reaction to aminoglycoside antibiotics or other drugs. Known history of human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, or any uncontrolled active systemic infection requiring intravenous antibiotics. Non-hematologic malignancy-related hepatic or renal impairment, including any of the following: ALT > 3 × ULN, AST > 3 × ULN, total bilirubin (TBIL) > 2 × ULN, or creatinine clearance < 30 mL/min. History of myocardial infarction, percutaneous coronary intervention (including coronary angioplasty or stenting), unstable angina, active arrhythmia, or other clinically significant cardiovascular disease within the past 12 months. Any other serious medical condition that, in the opinion of the investigator, may interfere with the study treatment or increase risk to the patient (e.g., poorly controlled diabetes, active peptic ulcer disease, severe respiratory or circulatory disease, severe autoimmune disease, congenital immunodeficiency, uncontrolled severe infection, or other conditions with high risk of clinical deterioration). History of severe immediate-type hypersensitivity reaction to any medication required during the treatment process, or history of severe allergy to biologics (including antibiotics). Female patients who are pregnant or breastfeeding (preconditioning chemotherapy regimen poses potential risk to the fetus or infant). In the opinion of the investigator, the patient is unlikely to comply with all required study visits, procedures, or long-term follow-up; has poor willingness or ability to participate and cooperate fully; or has insufficient compliance (as judged by the patient and/or family). History of other malignancy, unless the patient has been disease-free and has received no antitumor therapy for at least 3 years (exceptions: non-melanoma skin cancer, and carcinoma in situ of the cervix, bladder, or breast). Receipt of a live vaccine within 6 weeks prior to initiation of the preconditioning regimen. Major surgery (excluding lymph node biopsy) within the past 14 days, or anticipated need for major surgery during the treatment period. Any other serious physical or psychiatric illness, or clinically significant laboratory abnormality, that may increase the risk associated with study participation, interfere with the interpretation of study results, or render the patient unsuitable for participation in the opinion of the investigator.
引自 ClinicalTrials.gov, NCT07489989, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07489989,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。